Covid: New data shows GSK-Vir drug works against all Omicron mutations

British drugmaker GSK said on Tuesday its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.

The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.

Last week, another pre-clinical data showed that the drug had worked against key mutations of the Omicron variant.

Sotrovimab is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron